Literature DB >> 12877571

Bioequivalence evaluation of three different oral formulations of ciprofloxacin in healthy volunteers.

Manuela T Maya1, Nuno J Gonçalves, Nuno E Silva, Augusto E Filipe, José A Morais.   

Abstract

Two bioequivalence studies were performed in twenty four healthy male volunteers with the objective of comparing the bioavailability of three different oral formulations of ciprofloxacin as immediate release tablets 250, 500 and 750 mg (test formulations) with a reference formulation at 500 and 750 mg strengths forms. In study 1, the subjects were enrolled in a single-dose, open-label, 3-period, crossover randomised study, designed to compare the bioavailability of two test formulations of ciprofloxacin (A and B) as 250 and 500 mg tablets, compared to the reference formulation (C), as 500 mg tablets. In study 2, the same 24-subjects were included in a single-dose, open-label, 2-period, crossover randomised study, designed to compare the bioavailability of one test formulation of ciprofloxacin (A) as compared to the reference formulation (B), both products as 750 mg tablets. In both studies multiple blood samples were collected over 24 hours post-dosing. One washout period of six days was observed between the periods. Plasma was harvested and assayed for ciprofloxacin using a selective and sensitive high-performance liquid chromatography (HPLC) method with UV detection. The pharmacokinetic parameter values of Cmax and tmax were obtained directly from plasma data, ke was estimated by log-linear regression, and AUC was calculated by trapezoidal rule. Different statistical tests were performed on the basis of untransformed and log-transformed data and the overall residual variance from ANOVA. Assuming the accepted tolerance intervals, a beta-error of 20% and 90% confidence intervals (alpha = 0.10) of all the generally accepted tests (Westlake, Schuirmann test and Wilcoxon-Tukey nonparametric tests) showed that the formulations can be considered as bioequivalent with respect to the extent of absorption, given by the AUC0-infinity and with respect to rate of absorption as assessed by Cmax and tmax.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12877571     DOI: 10.1007/BF03190501

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  9 in total

1.  Simple high-performance liquid chromatographic assay for the determination of ciprofloxacin in human plasma with ultraviolet detection.

Authors:  M T Maya; N J Gonçalves; N B Silva; J A Morais
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-05-05

2.  Sample size determination for bioequivalence assessment by means of confidence intervals.

Authors:  E Diletti; D Hauschke; V W Steinijans
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992

3.  Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.

Authors:  D Fabre; F Bressolle; R Gomeni; C Arich; F Lemesle; H Beziau; M Galtier
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  Bioequivalence evaluation of 2 different oral formulations of ciprofloxacin in healthy volunteers.

Authors:  I Galicia; J Frias-Iniesta; A J Carcas; A Soto; E Gomez; E Miranda; A Fernandez; C Montuenga
Journal:  Int J Clin Pharmacol Ther       Date:  1998-05       Impact factor: 1.366

5.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

6.  Renal elimination of sulfo-ciprofloxacin, a new metabolite of ciprofloxacin.

Authors:  K Borner; H Lode; G Höffken
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

7.  Statistical aspects of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  Biometrics       Date:  1979-03       Impact factor: 2.571

8.  The distribution of ciprofloxacin and its metabolites in human plasma, pulmonary and bronchial tissues.

Authors:  N Bacracheva; H Scholl; Z Gerova; P Chervenakov; P Dobrev; V Vlahov
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-09

9.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.